NEW YORK – It's been 10 years since the US Food and Drug Administration approved the first indication for Merck's Keytruda (pembrolizumab), and over that time, the immunotherapy has racked up 41 ...

The First Lady, Rebecca Akufo-Addo, has lauded the Merck Foundation for its impactful campaign to break the stigma surrounding infertility in Africa and Asia, citing its "More than a Mother ...

The pace of mergers and acquisitions remained strong this week, with Kraft Heinz, Engineering software firm Altair, and Spirit Airlines grabbing headlines. Here's a list of other key deals this week: ...

Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company ...

CBSE Class 12 Subject-Wise Lab Manual: The Central Board Of Secondary Education has made available the lab manuals for classes 12 for all the subjects. Students can download the PDFs of these lab ...

Lab Manual Class 10: The Central Board of Secondary Education (CBSE) is a national level board of education for public and private schools in India. For the students of class 10, CBSE has made a ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired ... weight-loss drug helps nearly 99% of patients remain diabetes-free November 13, 2024 The crypto industry is pushing for an ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of ...

Today, a brief rundown of news from Merck & Co. and Roche, as well as updates from Sangamo Therapeutics, UCB and Catalent that you may have missed. MacroGenics, a developer of antibody medicines for ...

Merck’s MRK stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals industry. The stock has also underperformed the sector and the S&P 500 ...